Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant Inc (NQ: IMVT )

20.66 -0.02 (-0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 838,142
Open 20.82
Bid (Size) 20.66 (2)
Ask (Size) 21.92 (2)
Prev. Close 20.68
Today's Range 20.40 - 21.02
52wk Range 3.145 - 24.18
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To Know
 
Via Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
Via Investor Brand Network

Performance

YTD
+10.19%
+10.19%
1 Month
+13.70%
+13.70%
3 Month
+21.89%
+21.89%
6 Month
+48.95%
+48.95%
1 Year
+402.68%
+402.68%

More News

Read More
Analyst Expectations for Immunovant's Future
Via Benzinga
Recap: Immunovant Q4 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Analyst Expectations for Immunovant's Future
Via Benzinga
7 Analysts Have This to Say About Immunovant
Via Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
Via Investor Brand Network
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
Via Benzinga
Analyst Expectations for Immunovant's Future
Via Benzinga
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
Via Benzinga
What 6 Analyst Ratings Have To Say About Immunovant
Via Benzinga
6 Analysts Have This to Say About Immunovant
Via Benzinga
Where Immunovant Stands With Analysts
Via Benzinga
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
From Immunovant Inc.
Via GlobeNewswire
Immunovant: Q2 Earnings Insights
Via Benzinga
Why Immunovant Stock Is Skyrocketing This Week
Via The Motley Fool
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
From Immunovant Inc.
Via GlobeNewswire
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.